INCIDENCE AND RISK FACTORS FOR LATE CYTOMEGALOVIRUS (CMV) BLOOD INFECTIONS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (ALLOHCT) (EHA 2025) - May 16, 2025 - Abstract #S303; Pres time: Jun 13, 2025; 05:45 PM - 06:00 PM; Location: Brown Hall 1; "57% of patients received post-transplant cyclophosphamide (PTCY) for GVHD prophylaxis and 43% received letermovir at any time during their alloHCT...-10.4] 1.9 [0.6-6.4] GVHD Prophylaxis Cyclophosphamide containing 1 1 Methotrexate containing 3.1 [1.5-6.5] 1.4 [0.6-3.5] Other 7.9 [ .8- .0] 4... Multiple risk factors affect the incidence of CMV infection after day+90 of alloHCT. Some increase risk throughout the alloHCT process while others have time-limited effects. Consideration of these risk factors relative to the patient's alloHCT course can potentially predict the risk of CMV infection."
Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation
|
|
George Chen; Roland Bassett; Rohtesh Mehta; Fareed Khawaja; Yosra Aljawai; Uday Popat; Richard E. Champlin; Elizabeth J. Shpall
|